Santen 色界吧 has signed a licensing agreement with RemeGen for the RC28-E intravitreal injection, a dual-target fusion protein designed to treat retinal diseases.
The agreement, facilitated through Santen’s subsidiary in China, grants the company exclusive rights to develop, manufacture and market RC28-E across Hong Kong, Macau, Mainland China, Indonesia, Malaysia, the Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
RemeGen will receive an upfront payment of 250m yuan ($34.8m), milestone payments for development and regulatory achievements totalling up to 520m yuan ($72.3m), and up to 525m yuan ($73.09m) sales milestone payments.
The company will also receive additional net sales-based royalties.
RemeGen CEO Dr Fang Jianmin stated: 鈥淪anten brings over 130 years of ophthalmic expertise and a robust global commercial network spanning more than 60 countries and regions.
鈥淎s RemeGen independently developed a Category 1 innovative drug, RC28-E is approaching the critical stage of BLA submission.鈥�
US Tariffs are shifting - will you react or anticipate?
Don鈥檛 let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataRC28-E is a bi-specific fusion protein that targets vascular endothelial growth factor and fibroblast growth factor.
It is currently under clinical development for conditions such as diabetic macular oedema, wet age-related macular degeneration and diabetic retinopathy.
Recent findings from a Phase II clinical trial of RC28-E for diabetic macular oedema were presented at the 2025 Annual Meeting of the Association for Research in Vision and Ophthalmology.
Results indicated that the treatment improved best-corrected visual acuity while reducing central subfield thickness, and was well-tolerated by patients.
Santen president and CEO Takeshi Ito stated: 鈥淩emeGen has demonstrated outstanding capabilities and innovation in the field of novel drug development.
鈥淎s RemeGen鈥檚 flagship pipeline in ophthalmology, RC28-E offers differentiated advantages by simultaneously targeting angiogenesis and fibrosis, potentially providing a new therapeutic approach and innovative option for the treatment of fundus diseases.鈥�
